ClinicalTrials.gg
CompletedNCT04959981HERKULES-2Updated Jul 25, 2023

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

A Phase 1 interventional study of ERAS-007 and ERAS-601 in Advanced Non-squamous Non-small-cell Lung Cancer, sponsored by Erasca, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-07-25.

Sponsored by Erasca, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Noonan Syndrome with a site in United States — 6 open to participants now, 9 under way, 3 of them phase 3. Noonan Syndrome · United States.

Enrollment
14th of 17
24 · median 56
Started
2021
the only one that year
Phase 1
7 of 20
none open now
Registered
14th of 20
by date
Lead sponsor
2 of 20
Erasca, Inc.

Among the 20 studies in Noonan Syndrome with a site in United States, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 1, and was the 14th registered.

Noonan Syndrome

49 studies on the registry are indexed under Noonan Syndrome; 21 are open to participants now.

Browse Noonan Syndrome studies →

Open to participants now

6 of the 20 studies in Noonan Syndrome with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Noonan Syndrome studies recruiting now, 10 (63%) set no upper age limit and 4 (25%) stop at 75 or younger; 13 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Noonan Syndrome with a site in United States, or all of them as a file.
02

Study summary

  • To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung cancer (NSCLC).
  • To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies.
  • To evaluate the antitumor activity of ERAS-007 or ERAS-601 in combination with other cancer therapies.
  • To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.
Read the detailed description

This is a Phase 1b, open-label, multicenter master protocol evaluating safety, tolerability, and antitumor activity of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced NSCLC. The study will commence with the following dose escalation cohorts: ERAS-007 plus osimertinib in study participants with advanced NSCLC harboring epidermal growth factor receptor-sensitizing mutation(s) (EGFRm); ERAS-007 or ERAS-601 plus sotorasib in study participants with advanced NSCLC harboring Kirsten rat sarcoma G12C mutation (KRAS G12Cm). Dose expansion will follow and will evaluate ERAS-007 or ERAS-601 drug combinations administered at the RD identified from each respective dose escalation cohort in study participants with advanced EGFRm or KRAS G12Cm NSCLC.

03

Conditions studied

  • Advanced Non-squamous Non-small-cell Lung Cancer

Keywords

  • EGFR
  • epidermal growth factor receptor
  • mutation
  • biomarker
  • NSCLC
  • Tagrisso
  • osimertinib
  • ERK
  • MAPK
  • sotorasib
  • Lumakras
  • KRAS
  • G12C
  • SHP2
  • PTPN11
  • molecular alterations
  • Kirsten rat sarcoma
  • Non-small cell lung cancer
  • Lung neoplasms
  • Thoracic neoplasms
  • ERAS-601
  • ERAS-007
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Willing and able to give written .
  • Have or cytologically confirmed NSCLC, with presence of EGFR mutation(s) sensitive to EGFR inhibitors, or KRAS G12C mutation.
  • per (RECIST) v1.1.
  • Adequate bone marrow and organ function.
  • Have performance status of 0 or 1.
  • Willing to comply with all protocol-required visits, assessments, and procedures.
  • Able to swallow oral medication.

Exclusion criteria

Exclusion Criteria:

  • Concurrent treatment with any systemic anticancer therapy for NSCLC, including any approved or agent.
  • For participants with EGFRm NSCLC: prior therapy with a RAS, RAF, MEK, or ERK inhibitor.
  • For participants with KRAS G12Cm NSCLC: prior therapy with a SHP2, ERK, or KRAS G12C inhibitor (depending on which cohort is being considered for enrollment).
  • Palliative radiotherapy within 7 days of enrollment.
  • History of unacceptable toxicity to treatment with osimertinib or sotorasib.
  • Major surgery within the 28 days of enrollment.
  • Unresolved toxicities from prior systemic therapy greater than grade 1 at time of enrollment, except for toxicities not considered a safety risk (eg, alopecia, vitiligo, and grade 2 neuropathy due to prior chemotherapy).
  • History of another ≤5 years prior to first dose, except for patients who are disease-free for >2 years after treatment with curative intent or who have carcinoma in situ.
  • Symptomatic and unstable , or spinal cord compression, except for patients who have completed definitive therapy (surgery or radiotherapy), are not on , and have a stable neurologic status for a least 2 weeks after completion of the definitive therapy and steroids.
  • History of or clinically active ILD, drug induced ILD, or radiation pneumonitis that required steroid treatment.
  • Impaired cardiovascular function or cardiovascular disease.
  • History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO.
  • Any evidence of severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or laboratory finding that renders the patient inappropriate to participate in the study.
  • Pregnant or breastfeeding women.
  • to osimertinib or sotorasib use as per local label.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Dose Escalation (Part 1): ERAS-007 plus osimertinib

    ERAS-007 will be orally administered in combination with osimertinib to study participants with EGFRm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: ERAS-007 · Drug: Osimertinib

  • Experimental
    Dose Escalation (Part 2): ERAS-007 plus sotorasib

    ERAS-007 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: ERAS-007 · Drug: Sotorasib

  • Experimental
    Dose Escalation (Part 3): ERAS-601 plus sotorasib

    ERAS-601 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.

    Drug: ERAS-601 · Drug: Sotorasib

  • Experimental
    Dose Expansion (Part 4): ERAS-007 plus osimertinib

    ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with osimertinib to study participants with EGFRm NSCLC.

    Drug: ERAS-007 · Drug: Osimertinib

  • Experimental
    Dose Expansion (Part 5): ERAS-007 plus sotorasib

    ERAS-007 will be orally administered at the recommended dose (as determined from Part 2) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.

    Drug: ERAS-007 · Drug: Sotorasib

  • Experimental
    Dose Expansion (Part 6): ERAS-601 plus sotorasib

    ERAS-601 will be orally administered at the recommended dose (as determined from Part 3) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.

    Drug: ERAS-601 · Drug: Sotorasib

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    Based on adverse events observed

    Time frame: Study Day 1 up to Day 22

  2. Maximum Tolerated Dose (MTD)

    Based on adverse events observed

    Time frame: Study Day 1 up to Day 22

  3. Recommended Dose (RD)

    Based on adverse events observed

    Time frame: Study Day 1 up to Day 22

  4. Adverse Events

    Incidence and severity of treatment-emergent AEs and serious AEs

    Time frame: Assessed up to 24 months from time of first dose

Secondary outcomes

  1. Plasma concentration (Cmax)

    Maximum plasma concentration of ERAS-007 or ERAS-601 and other cancer therapies

    Time frame: Study Day 1 up to Day 22

  2. Time to achieve Cmax (Tmax)

    Time to achieve maximum plasma concentration of ERAS-007 or ERAS-601 and other cancer therapies

    Time frame: Study Day 1 up to Day 22

  3. Area under the curve

    Area under the plasma concentration-time curve of ERAS-007 or ERAS-601 and other cancer therapies

    Time frame: Study Day 1 up to Day 22

  4. Half-life

    Half-life of ERAS-007 or ERAS-601 and other cancer therapies

    Time frame: Study Day 1 up to Day 22

  5. Objective Response Rate (ORR)

    Based on assessment of radiographic imaging per RECIST version 1.1

    Time frame: Assessed up to 24 months from time of first dose

  6. Duration of Response (DOR)

    Based on assessment of radiographic imaging per RECIST version 1.1

    Time frame: Assessed up to 24 months from time of first dose

07

Study locations

11 sites
  • City of Hope
    Duarte, California 91010, United States
  • UC Irvine, Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • UC Los Angeles
    Santa Monica, California 90404, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Research Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Hackensack University Medical Center (John Theurer Cancer Center)
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute (Tennessee Oncology)
    Nashville, Tennessee 37203, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Apr 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2021
First posted
Jul 13, 2021
StartActual
Sep 2, 2021
Primary completionActual
Apr 27, 2023
CompletionActual
Apr 27, 2023
Last update
Jul 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04959981
Lead sponsor
Erasca, Inc.
Responsible party
Sponsor
First posted
Jul 13, 2021
Start date
Sep 2, 2021
Primary completion
Apr 27, 2023
Completion
Apr 27, 2023
Last update
Jul 25, 2023

Study contacts

Joyce Antal
study director · Senior Director, Clinical Development

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ASN-007 · SHP2 Inhibitor ERAS-601 · Sotorasib

Start the discussion